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Abstract
Intracellular cobalamin metabolism (ICM) defects can be present as autosomal recessive
orX-linked disorders. Parenteral hydroxocobalamin (P-OHCbl) is themainstay of therapy,
but the optimal dose has not been determined. Despite early treatment, long-term compli-
cations may develop. We have analyzed the biochemical and clinical responses in five
patients with early onset of different types of ICMdefects (cblC: patients 1-3; cblA: patient
4; cblX: patient 5) following daily P-OHCbl dose intensification (DI). In patient
4, P-OHCbl was started at age 10 years and in patient 5 at age 5 years. OHCbl was formu-
lated at either, 5, 25, or 50 mg/mL. P-OHCbl was intravenously or subcutaneously
(SQ) delivered, subsequently by placement of a SQ injection port except in patient 4. In all
patients, homocysteine andmethylmalonic acid levels, demonstrated an excellent response
to various P-OHCbl doses. After age 36 months, patients 1-3 had a close to normal neuro-
logical examination with lower range developmental quotient. In patient 3, moderate
visual impairment was present. Patient 4, at age 10 years, had normal renal, visual and cog-
nitive function. In cblX patient 5, epilepsy was better controlled. In conclusion, P-OHCbl-
DI caused an excellent control of metabolites in all patients. In the three cblC patients,
comparison with patients, usually harboring identical genotype and similar metabolic pro-
file, was suggestive of a positive effect, in favor of clinical efficacy. With P-OHCbl-DI,
CblA patient has been placed into a lower risk to develop renal and optic impairment. In
cblX patient, lower P-OHCbl doses were administrated to improve tolerability.
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1 | INTRODUCTION
Autosomal recessive disorders of intracellular cobalamin
metabolism (ICM), designated as cblA-cblJ,1 can give rise,
either to a deficiency of methylmalonyl-CoA mutase (cblA,
cblB, and cblD variant 2) resulting in isolated met-
hylmalonic aciduria, or to a deficiency of methionine
synthase (cblD variant 1, cblE, and cblG) resulting in iso-
lated homocystinuria or to both, (cblC, classic cblD, cblF,
and cblJ), resulting in combined methylmalonic aciduria and
homocystinuria. Cobalamin C (cblC) defect is the most com-
mon subgroup of inborn errors in ICM.
The spectrum of this disorder extends from fetal to
adulthood period, with perinatal, early onset (EO) infantile
presentation before 1 year of age, childhood (CO) (after
the first year of age), adolescent and adult onset. The EO
is the most frequently recognized. Infrequently (10%-20%),
at initial presentation, Cbl C patients presented a
hemolytic-uremic syndrome (HUS).2,3 In the Caucasian
population, the cblC variant c.271dupA, p.(Arg91fs),
accounts for 42% of mutant alleles.4 In Europeans, both
variants c.271dupA and c.331C>T, in the homozygous or
compound heterozygous state, were primarily observed in
EO cases.3-5 Genotype has been reported as very predictive
of visual impairment, homozygous c.271dupA p.(Arg91fs)
patients being severely and universally affected.6 P-OHCbl
is the mainstay of therapy.2,7 In a few patients, with sub-
optimal metabolic control, P-OHCbl dose escalation has
been tried8,9 in order to improve long-term outcome. In
cblA defect, caused by a pathogenic MMAA variant,10
chronic renal disease (CRD) may constitute long-term
sequelae, despite OHCbl therapy11,12 and rarely, mild optic
nerve atrophy.13 Therapy involves OHCbl.14 cblX defect,
an X-linked ICM disorder, with methylmalonic acidemia
and homocysteinemia, is caused by a pathogenic HCFC1
variant, resulting in transcriptional dysregulation involving
many genes. Despite representing a broader neu-
rodevelopmental phenotype, severe MMACHC down-
regulation has been observed in cblX patients.15The aim of
this study was to evaluate the clinical and biochemical
response of P-OHCbl-DI in patients with different types of
EO ICM defects, including cblC, cblA, and cblX.
2 | PATIENTS AND METHODS
In five patients, with EO of different ICM defects (cblC:
patients 1, 2, 3; cblA: patient 4; cblX: patient 5), clinical and
biochemical responses were evaluated following daily P-
OHCbl-DI. OHCbl was formulated at either, 5, 25, or
50 mg/mL. P-OHCbl doses were intravenously (IV) or sub-
cutaneously (SQ) delivered, subsequently by placement of a
subcutaneous injection port (i-Port Advance TM) to
minimize cutaneous punctures except in patient 4. Neuro-
psychologic development was assessed by using ET 6-6-R16
in cblC patients, and WISC-IV (verbal scale) in cblA patient.
In all patients, brain MRI was performed as well as in cblC
patients 1 and 3, optical coherence tomography (OCT). All
procedures followed were in accordance with the Helsinki
Declaration of 1975.
3 | PATIENT 1 AND 2
Since birth, patients 1 and 2, twin girls, presented anorexia,
lethargy, failure to thrive, neutropenia (240 and 370 G/L,
normal >1500) and nystagmus. On admission, at age
3 weeks, both plasma total homocysteine (tHcy) and uri-
nary methylmalonic acid (uMMA) values were elevated.
Subsequently, both infants were treated (day one) with
P-OHCbl (0.31 mg/kg/day) supplemented with oral betaine
(100 mg/kg/day), folinic acid (5 mg/day), and oral
L-carnitine (50 mg/kg/day), which was followed by clinical
improvement. The biomarker response, at onset and follow-
ing P-OHCbl-DI, is represented in Figure 1A-F. Molecular
analysis revealed homozygosity for the c.271dupA (p.
Arg91fs) variant. Twin zygosity DNA testing confirmed
monozygotic twins. At age 32 months, in both patients, no
abnormal eye movements, such as nystagmus, were
observed, except in patient 1, mild intermittent, small ocu-
lar jerks. Daily P-OHCbl dose was 2.40 mg/kg. In both
siblings, the neurological examination was normal except
for hypotonia. Patient 1 walked independently at age
20 months and patient 2 at age 25 months. At age 3 years,
both infants could pronounce three-word sentences in two
languages and use two personal pronouns. Both patients
could build a tower of more than six blocks, master her pin-
cer grasp with right-hand preference and making circular
and both horizontal and vertical line with three-digital
grasp in patient 1 and palmar grasp in patient 2. Results of
developmental, ophthalmologic and MRI evaluations are
shown in Table 1.
4 | PATIENT 3
At age 3 weeks, cblC patient 3, a boy, presented anorexia
and peri-orificial dermatitis. He was admitted at age 27 days
with multi-organ failure and metabolic acidosis (anion gap:
21 mmol/L, normal 8-16). He had a HUS, characterized by
the triad22 of hemolytic anemia (8.0 g/dL, normal>10), ure-
mia (80-117 mg/dL, normal <50) and thrombocytopenia
(10 G/L, normal >230). On blood smear, schizocytes (2%)
as well as neutropenia (620 G/L, normal >1500) were found.
Following a high tHcy level, (at day 2), IV OHCbl
(4.1 mg/kg/day) was administrated, supplemented with oral
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betaine (150-200 mg/kg/24 hours) and both IV folinic acid
(5 mg) and L-carnitine (100 mg/kg). In spite of infrequently
used,23 oral methionine dose was initially started at
33 mg/kg/day and interrupted at age 10 months. The bio-
marker response at onset and following P-OHCbl-DI is
reported in Figure 1G,H. Molecular analysis revealed the
FIGURE 1 OHCbl dose reduction of tHcy, MMA, uMMA and csf-MMA values and increase in methionine levels. Normal levels: tHcy
<10.0 μmol/L, methionine 10-40 μmol/L, uMMA <17 μmol/mmol/creat, MMA, and csf-MMA 0 μmol/L). cblC patients 1 and 2: A and D, tHcy (black
line and double arrow) levels were obtained as mean between (n = 4) age 1.0 and 3.1 months; (n = 2) age 5.0 and 6.9 months); (n = 2), 13.6 and
14.5 months; (n = 3) age 21.9 and 31.8 months); (n = 2) age 36.7 and 38.4 months). The significance has been determined by unpaired t test (**P = .01,
*P < .05) for plasma homocysteine levels (double arrow) and is referring to the previous values (double arrow). B and E, uMMA (dotted line) levels were
obtained as mean (n = 4) between age 1.0 and 3.1 months; (n = 2) between age 5.0 and 6.9 months); (n = 2) between age 21.9 and 31.8 months). C and F,
MMA, initial csf-MMA and at age 35.7 months. cblC patient 3: G, tHcy (both horizontal black line and double arrow) levels were obtained as mean
between (n = 2) age 4.8 and 5.1 months; (n = 7) age 6.9 and 18.4 months; (n = 4) age 21.2 and 38.8 months). Vertical black arrow: (at age 6.2 months)
double dose during 48 hours. The significance has been determined by unpaired t test (*P < .05) for tHcy (horizontal double arrow) and is referring to the
previous values (horizontal double arrow). (H) uMMA (n = 6) and MMA (n = 5) (horizontal dotted line) levels were obtained as mean between age 6.9 and
18.4 months. Initial csf-MMA levels. cblA patient 4: (I) uMMA (n = 7) (dotted line) levels were obtained as mean between age 6.9 and 18.4 months (range:
77-2542). cbl X patient 5: J, dotted line: oral OHCbl *: P-OHCbl (5 mg twice a week = 0.07 mg/kg/day) black vertical arrow: no OHCbl during 7 days.
Abbreviations are as follows: m: months; yrs: years; tHcy: plasma total homocysteine; (u) (csf) MMA: (urinary) (cerebro-spinal fluid) methylmalonic acid;
ND: not detected; IV-OHCBL: intravenous hydroxocobalamin, S/Q-OHCBL: subcutaneous hydroxocobalamin (formulated at 5 mg/mL and 25 mg/mL); i-
port: subcutaneous injection port (i-port advance TM) (formulated at 25 mg/mL and/or 50 mg/mL). OHCbl blood levels: (dose of 2.41 mg/kg/day:
17.5 × 106 pg/mL in cblC patient 1 and 17.0 × 106 pg/mL in cblC patient 2); (dose of 2.98 mg/kg/day: 11.0 × 106 pg/mL in cblC patient 3); (dose of
0.88 mg/kg/day: 4.80 × 106 pg/mL in cblA patient 4); (dose of 0.21 mg/kg: 3.40 × 106 pg/mL in cblX patient 5) (normal <1999 pg/mL)
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homozygous c.271dupA (p.Arg91fs) variant. Progressively,
multi-organ failure resolved. At age 5 months, he had cho-
langitis (total biliary acid levels 20.5 μmol/L, normal <10). P-
OHCbl doses were increased from a mean value of 2.50 to
3.20 mg/kg/day resulting in normal total plasma biliary acid
levels at age 22 months (3.3 μmol/L, normal<10). Despite mod-
erate visual impairment with right head tilt and nystagmus,
visual performance improved both in the ability to fix and
FIGURE 1 Continued
SCALAIS ET AL. 73
follow. He walked independently at age 20 months. At age
24 months, he could speak several words in two languages and
use onomatopoeia and gestural support (bye, bravo, pointer
finger such as designate familiar objects). Results of develop-
mental, ophthalmologic, and MRI evaluations are shown in
Table 1.
FIGURE 1 Continued
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5 | PATIENT 4
Patient 4, a boy, was born at term from non-consanguineous
parents. He started to walk at age 18 months and speak sen-
tences at 2½ years. Before admission, he was diagnosed as
hypotonic with poor head control. At age 6 months, he
showed metabolic acidosis with hyperketonemia. uMMA
levels were markedly increased. Molecular analysis rev-
ealed a compound heterozygous variant in MMAA gene
located on chromosome region 4q31.21, c.439+4_439
+7del, p.? inherited from the mother and c.593_596del, (p.
Thr198fs) inherited from the father. Initially, he was
treated with dietary protein restriction supplemented with
oral OHCbl (1 mg). He had several episodes of metabolic
acidosis during intercurrent febrile infections. At age
9 years, daily P-OHCbl was initiated. The biomarker
response, at onset, at age 9 years, and following P-OHCbl-
DI is reported in Figure 1I. At age 10 years, his physical
and neurological examination was normal. Ophthalmologi-
cal examination was normal including eye fundus and
visual field as well as his renal function. Performed at age
11½ years, both brain MRI and MR spectroscopy were
normal. Cognitive level was also normal at age 8 years
(WISC-IV: verbal scale 99).
6 | PATIENT 5
Patient 5, a boy, previously reported,24 showed, at age
10 days, refractory seizures and high CSF glycine mimicking
non-ketotic hyperglycinemia. Both urinary methylmalonic
acid and plasma homocysteine were elevated. At age 5 years,
he was diagnosed to be affected by the cblX defect. He
resulted to carry a variant, in the global transcriptional
coregulator, HCFC1. A hemizygous variant, c.2728A>G, (p.
Lys910Glu) was also detected in ATRX. Clinically, this
patient was characterized by severe developmental disability
and intractable epilepsy. P-OHCbl (0.53 mg/kg/week) pro-
duced seizure and or involuntary movement exacerbation,
despite metabolic improvement. However, macrocytosis was
not corrected (mean corpuscular volume [MCV] 103.2 μ3,
normal 76-91). At age 7 years, following a very slow increase
in P-OHCbl doses, as shown in Figure 1J,K, a better improve-
ment in seizure control was obtained, but not in neurological
development. Macrocytosis, although less marked, was still
present (MCV 99.5 μ3 vs 105.4 and 106.6, normal 76-91)
suggesting that his P-OHCbl dose was not yet sufficient.
7 | DISCUSSION
The three cblC patients harbor the most frequent variant which is,
in the Caucasian population, c.271dupA (p.Arg91fs), located in
the MMACHC gene. Being homozygous, they belong to the EO
with the highest risk to develop maculopathy, progressive reti-
nopathy and cognitive delay.6,25,26 Usually, well treated infants,
maintained, on follow-up, moderately elevated plasma tHcy
levels (20-80 μmol/L) as well uMMA (10-100 μmol/mmol/Cr).1
In contrast, in the three cblC patients, P-OHCbl-DI produced
excellent biochemical responses such as lower range plasma tHcy
and higher methionine values (Figure 1A,D,G) as well as low
uMMA, csf-MMA and MMA levels (Figure 1B,C,E,F,H). Com-
pared to cblC patients 1 and 2, cblC patient 3, initially required
higher OHCbl doses, to control plasma tHcy values. This discrep-
ancy could be related to disease severity, including HUS, multi-
organ failure, metabolic acidosis and poor perfusion. Not surpris-
ingly, before hospital discharge, at age 2.2 months, P-OHCbl,
being formulated at 5 mg/mL, had to be temporally administrated
at lower dose (1.22 mg/kg), which raised plasma tHcy and uri-
nary MMA levels (Figure 1G,H). Subsequently, by using P-
OHCBL-DI (2.50 mg/kg), formulated at 25 mg/mL and
50 mg/mL, plasma tHcy and uMMA levels decreased to lower
values. At age 6.2 months, cblC patient 3 received, following
medical order misinterpreted, double P-OHCbl dose
(5.50 mg/kg/day), for 48 hours. Subsequently, plasma tHcy
dropped from 22.5 to 13.5 μmol/L (Figure 1G). However, how
can we assume that such as P-OHCbl-DI could have had thera-
peutic effects on the three cblC patients? Although, the three cblC
patients were promptly treated with P-OHCbl-DI, they were ini-
tially already symptomatic and EO CblC defect presents both
developmental and degenerative features. Therefore, it was not
surprising to have observed some degree of developmental and
ocular manifestations in the three cblC patients. Our study was
limited by the small number of patients who could not be ran-
domized to different treatment doses. However, we found indirect
evidence for the efficacy of higher doses of OHCbl. Following P-
OHCbl-DI, nystagmus disappeared in cblC patients 1 and 2 and
visual behavior significantly improved in cblC patient 3 with no
sign of ocular disease progression at age 3 years. Compared to
previous studies (Table 1), most of the EO cblC patients, usually
harboring a homozygous c.271dupA (p.Arg91fs), with high ini-
tial tHcy (>60 μmol/L) or high homocystine (>30 μmol/L) levels
and treated at onset with low P-OHCbl dose, have prominent
developmental delay, autistic features, pigmentary retinitis, optic
atrophy, marked MRI abnormalities (ventriculomegaly, WM
atrophy) and persistent moderately elevated plasma tHcy
levels.17-21 Importantly, homozygous c.271dupA patients with, at
onset, low plasma tHcy (<60 μmol/L) or homocystine (<
30 μmol/L), may have a better prognosis.27
Similarly, the response of HUS to higher-doses of
OHCbl in two CO cblC siblings has been specified.28
These siblings required a serum cobalamin concentration
of approximately 1 × 106 pg/mL to obtain clinical and
biochemical responses. In another study,8 an EO cblC
patient, with PR and mild developmental delay received,
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at 1-month interval, an increasing dose regimen
(0.35 mg/kg). This strategy resulted in an 80% and 55%
reduction of plasma MMA and tHcy, respectively. Five
other EO cblC patients,9 aged between 5 and 14 years,
received also high P-OHCbl doses (0.1 mg/kg/day to
0.35 mg/kg/day), leading in patient 1 and patient 2 to
reduction of tHcy (30% and 17%).
In the cblA patient, the c.439+4_439+7del p (?) variant
inherited from the mother was predicted to delete the canoni-
cal splice site of exon 2.29 Being at risk, before P-OHCbl-
DI, to develop later mild optic neuropathy and/or CRD,
because of previous uMMA levels above the approximate
threshold of 2000 μmol/mmol/creatinine,12,13 the cblA
patient 4 had normal visual and renal function on early fol-
low up. The cblX patient responded biochemically and clini-
cally only after slowly increasing the P-OHCbl dose and
eventually achieved better seizure control. The poor clinical
outcome could be related mainly to the HCFC1 variant,
being a transcription factor involving many genes, and to a
lesser extend to the ATRX variant.
In conclusion, this study showed an excellent biochemical
response in all patients, and without significant side effects.
Among the metabolic biomarkers, plasma tHcy was the most
sensitive one. OHCbl dose-response relationship was only
observed with plasma tHcy levels. Sustained absolute normal
biomarker values were not obtained. In comparison with EO
cblC patients usually harboring identical genotype and similar
metabolic profile, we observed a better than expected outcome
in the three cblC patients, suggestive of a positive effect of P-
OHCbl-DI in favor of clinical efficacy, in particular, in view of
the absence of progressive retinopathy, a more favorable cogni-
tive outcome and improved brain myelination. With P-OHCbl-
DI, CblA patient has been placed into a lower risk to develop
CRD and or mild optic atrophy. In cblX patient, very slowly
progressive increase in P-OHCbl dose was necessary to
improve clinical tolerability and control seizures. Nevertheless,
long-term follow-up of both cblC and cblA patients as well as
larger population are needed to confirm this potential efficacy
of P-OHCbl-DI. High-dose of P-OHCbl was also easier to
administer to the child when P-OHCbl was formulated at
50 mg/mL and delivered by a SQ injection port.
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